We are live on ! Find out more
Stempoint Capital

Stempoint Capital Portfolio holdings

AUM $560M Turnover 64.34%
1-Year Est. Return 146.87%
This Fund
S&P 500
This Quarter Est. Return
+12.43%
1 Year Est. Return
+146.87%
3 Year Est. Return
+725.67%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$334M
AUM Growth
-$6.26M
Cap. Flow
-$29.8M
Cap. Flow %
-8.93%
Top 10 Hldgs %
55.99%
Holding
67
New
24
Increased
10
Reduced
18
Closed
13
Avg Time Held Equity + Options
0.3 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.3 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.4 years

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$17.4M
2
ACLX icon
Arcellx
ACLX
+$14.7M
3
IMCR icon
Immunocore
IMCR
+$11.5M
4
MRK icon
Merck
MRK
+$10.2M
5
IMVT icon
Immunovant
IMVT
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.38%
2 Financials 0.45%
3 Miscellaneous 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
SNDX icon
1
Syndax Pharmaceuticals
SNDX
$828M
$33.3M 9.98%
1,731,191
+319,015
+23% +$6.59M
2023 Q4
3 quarters
ROIV icon
2
Roivant Sciences
ROIV
$28B
$32M 9.57%
2,769,819
+57,078
+2% +$650K
2023 Q4
3 quarters
MRUS icon
3
DELISTED
Merus
MRUS
$21M 6.3%
421,222
+132,554
+46% +$6.92M
2023 Q4
3 quarters
IMVT icon
4
Immunovant
IMVT
$6.87B
$19.1M 5.73%
671,001
-340,878
-34% -$10.1M
2023 Q4
3 quarters
ARQT icon
5
Arcutis Biotherapeutics
ARQT
$3.46B
$16.5M 4.95%
1,778,318
+812,926
+84% +$8.02M
2023 Q4
3 quarters
FOLD icon
6
DELISTED
Amicus Therapeutics
FOLD
$15.8M 4.74%
1,481,809
-13,238
-0.9% -$144K
2023 Q4
3 quarters
BMY icon
7
Bristol-Myers Squibb
BMY
$125B
$14.2M 4.26%
+275,303
New +$12.9M
2024 Q3
0 quarters
APLT icon
8
DELISTED
Applied Therapeutics
APLT
$13.2M 3.96%
1,554,586
-656,734
-30% -$3.87M
2023 Q4
3 quarters
CRNX icon
9
DELISTED
Crinetics Pharmaceuticals
CRNX
$10.9M 3.27%
213,815
-337,280
-61% -$17.4M
2023 Q4
3 quarters
BHVN icon
10
Biohaven
BHVN
$2B
$10.8M 3.24%
216,440
-16,815
-7% -$654K
2023 Q4
3 quarters
PRAX icon
11
Praxis Precision Medicines
PRAX
$8.53B
$10M 3%
174,034
+144,775
+495% +$7.82M
2024 Q1
2 quarters
AUTL icon
12
Autolus Therapeutics
AUTL
$290M
$9.5M 2.84%
2,616,602
-46,130
-2% -$184K
2023 Q4
3 quarters
INCY icon
13
Incyte
INCY
$24.3B
$8.56M 2.56%
+129,490
New +$8.26M
2024 Q3
0 quarters
DNLI icon
14
Denali Therapeutics
DNLI
$2.89B
$8.22M 2.46%
282,050
+31,040
+12% +$769K
2024 Q2
1 quarter
DAWN icon
15
DELISTED
Day One Biopharmaceuticals
DAWN
$7.06M 2.11%
+506,978
New +$7.23M
2024 Q3
0 quarters
SLRN icon
16
DELISTED
ACELYRIN
SLRN
$6.5M 1.95%
+1,317,854
New +$6.8M
2024 Q3
0 quarters
SLNO icon
17
DELISTED
Soleno Therapeutics
SLNO
$6.22M 1.86%
+123,177
New +$5.9M
2024 Q3
0 quarters
CABA icon
18
Cabaletta Bio
CABA
$220M
$6.03M 1.81%
1,278,444
+100,339
+9% +$581K
2023 Q4
3 quarters
IMTX icon
19
Immatics
IMTX
$958M
$5.13M 1.54%
449,735
-52,472
-10% -$621K
2023 Q4
3 quarters
KROS icon
20
Keros Therapeutics
KROS
$222M
$5.05M 1.51%
+86,930
New +$4.29M
2024 Q3
0 quarters
ACLX icon
21
DELISTED
Arcellx
ACLX
$5.02M 1.5%
60,076
-220,633
-79% -$14.7M
2023 Q4
3 quarters
VTGN icon
22
VistaGen Therapeutics
VTGN
$8.34M
$4.9M 1.47%
1,846,792
-1,790
-0.1% -$6.11K
2023 Q4
3 quarters
NRIX icon
23
Nurix Therapeutics
NRIX
$1.56B
$4.56M 1.37%
203,015
-258
-0.1% -$5.84K
2024 Q2
1 quarter
TCRX icon
24
TScan Therapeutics
TCRX
$10.2M
$4.29M 1.28%
860,951
+15,882
+2% +$95.8K
2024 Q2
1 quarter
ZURA icon
25
Zura Bio
ZURA
$99.2M
$4.24M 1.27%
+1,044,168
New +$3.9M
2024 Q3
0 quarters

Similar funds

Stempoint Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Stempoint Capital held 67 positions worth $334M, down 1.8% from $340M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Stempoint Capital withdrew a net $29.8M in Q3 2024, closing 13 positions and reducing 18 holdings. Its most notable exit was Immunocore, an estimated $11.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Miscellaneous.

Against the trend, Stempoint Capital opened a new position in Bristol-Myers Squibb worth $14.2M.

  • Stempoint Capital's largest Q3 2024 buy was Bristol-Myers Squibb: 275,303 shares worth $14.2M.
  • Stempoint Capital added most to Arcutis Biotherapeutics in Q3 2024, an estimated $8.02M increase.
  • Stempoint Capital's biggest Q3 2024 reduction was Crinetics Pharmaceuticals, cutting an estimated $17.4M.
  • Stempoint Capital fully exited Immunocore in Q3 2024, selling an estimated $11.5M.
  • Stempoint Capital's ten largest holdings make up 56% of its $334M portfolio in Q3 2024.
  • Stempoint Capital opened 24 new positions and closed 13 in Q3 2024.
  • Stempoint Capital's portfolio value fell 1.8% quarter-over-quarter to $334M.

Based on Stempoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.